BEVACIZUMAB-AWWB

4692 reported adverse events

Drug classes: Vascular Endothelial Growth Factor Inhibitor [EPC]

BEVACIZUMAB-AWWB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BACTERIAL ENDOPHTHALMITIS 23 0.0865
1 RECTAL CANCER METASTATIC 6 0.0172
2 INTERCEPTED PRODUCT ADMINISTRATION ERROR 98 0.0128
3 PRODUCT SUBSTITUTION 5 0.0124
4 CARDIORENAL SYNDROME 6 0.0105
5 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 346 0.0102
6 AGE-RELATED MACULAR DEGENERATION 14 0.0092
7 GLIOBLASTOMA 15 0.0088
8 INTERCEPTED PRODUCT SELECTION ERROR 10 0.0077
9 REFUSAL OF TREATMENT BY PATIENT 50 0.0076
See all enriched reactions for BEVACIZUMAB-AWWB